AOD 9604
Fat Loss / MetabolicAlso known as: Anti-Obesity Drug 9604, Tyr-hGH Fragment 177-191
Mechanism
A modified fragment of human growth hormone (amino acids 177-191) designed specifically for fat loss. It mimics the fat-burning action of natural growth hormone without affecting blood sugar or muscle growth. It's taken as an injection or sometimes orally.
Technical detail
Modified C-terminal fragment of hGH (amino acids 177-191) with an added N-terminal tyrosine. Stimulates lipolysis via beta-3 adrenergic receptor pathway and inhibits lipogenesis. Does not compete with GH for the GH receptor, does not affect IGF-1 levels, and does not impair insulin sensitivity. Phase IIb trials showed modest fat loss. GRAS status granted by FDA for oral formulation (2020).
Effects
ADIPOSE TISSUE [Tier 1 – Human Clinical]: AOD-9604 (Anti-Obesity Drug 9604) is a modified fragment of human growth hormone (hGH amino acids 176-191) with a tyrosine substitution that retains lipolytic activity without the diabetogenic or growth-promoting effects of full GH. Stimulates lipolysis via beta-3 adrenergic receptor pathways in adipose tissue. Phase IIb trial (Stier et al., 2013) showed modest but statistically significant fat loss vs placebo in obese subjects over 12 weeks. Does NOT increase IGF-1, blood glucose, or insulin resistance — key differentiator from full GH or GH secretagogues. MUSCULOSKELETAL [Tier 2 – Limited Human]: Has been investigated for cartilage repair and osteoarthritis. Australian TGA granted it GRAS status for use in musculoskeletal applications. Early clinical data suggests potential for cartilage regeneration, but evidence remains limited. No significant anabolic or muscle-building effect — this is purely a fat-targeting fragment. METABOLIC [Tier 1 – Human Clinical]: Crucially, AOD-9604 does not impair glucose tolerance or create insulin resistance, which was the primary reason the fragment was developed — to isolate the fat-burning properties of GH without its metabolic side effects. Multiple human trials confirmed neutral effect on fasting glucose, HbA1c, and insulin sensitivity. CARDIOVASCULAR [Tier 3 – Preclinical]: No significant cardiovascular effects observed in human trials. Does not raise blood pressure or heart rate. Lipid panel effects modest and inconsistent across studies. ENDOCRINE [Tier 1 – Human Clinical]: Does not suppress endogenous GH production. Does not raise IGF-1 levels. No effect on thyroid function, cortisol, or sex hormones. This makes it one of the safest GH-related peptides from an endocrine standpoint.
Practitioner Guide
CLINICAL POSITIONING: AOD-9604 occupies a unique niche — it is the "GH fragment for people who want fat loss without GH side effects." Best suited for patients who cannot tolerate MK-677 (insulin resistance concerns), do not want IGF-1 elevation (cancer history concerns), or want targeted fat loss without the complexity of full GH optimization. DOSING PROTOCOLS: • Standard fat loss: 300 mcg/day subcutaneous, injected into abdominal fat pad, fasted (morning or before bed). Empty stomach critical — food within 30 min blunts absorption. • Aggressive protocol: 500 mcg/day split into 250 mcg AM (fasted) + 250 mcg PM (pre-bed, 3+ hours post-meal). • Cycle: 12 weeks on, 4 weeks off. Some practitioners run continuously for 6 months with blood work monitoring. • Injection site: Rotate between lower abdomen quadrants. Some practitioners believe injecting near target fat deposits improves local lipolysis (mechanistically plausible but unproven). REALISTIC EXPECTATIONS: AOD-9604 is a mild peptide. Expect 2-4 lbs additional fat loss over 12 weeks vs diet/exercise alone. It is NOT a replacement for semaglutide or tirzepatide for serious weight loss. Best positioned as an adjunct in a comprehensive protocol. STACKING: Commonly paired with CJC-1295/Ipamorelin (adds GH optimization without overlapping mechanisms), or with a GLP-1 agonist for enhanced fat loss. Can be used alongside fasting protocols — inject during the fast for maximum effect. BLOOD WORK: Minimal monitoring needed. Baseline and 8-week fasting glucose, insulin, IGF-1 (should remain unchanged — if IGF-1 rises, product may be contaminated with full GH or other GH fragments). Lipid panel optional. SOURCING CONCERNS: AOD-9604 is frequently underdosed or substituted in the gray market. Third-party testing essential. Should have no effect on IGF-1 — this is a quality control marker. If IGF-1 rises on "AOD-9604," the product is not pure. CONTRAINDICATION NOTES: One of the safest peptide options. No significant drug interactions. Safe in diabetics (does not affect glucose). Pregnancy/breastfeeding: insufficient data, avoid as precaution.
Dosing Protocols
- Dose
- 250mcg
- Frequency
- Once daily
- Timing
- Fasted — morning upon waking or before bed (at least 2 hours after last meal)
- Route
- subcutaneous
- Cycle
- 12-12 weeks
AOD 9604 stimulates lipolysis via beta-3 adrenergic pathway without affecting blood sugar or IGF-1. Fasted state is important for lipolytic activity. 250mcg is the conservative starting dose. Phase IIb trial used 1mg/day oral but SC is more common in practice. Effects are subtle — works best combined with caloric deficit and exercise. GRAS status for oral form granted by FDA (2020).
- Dose
- 500mcg
- Frequency
- Once daily or split 250mcg AM + 250mcg PM
- Timing
- Fasted — morning upon waking and/or before bed; both doses must be fasted (2+ hrs after food)
- Route
- subcutaneous
- Cycle
- 12-16 weeks
Higher dose for enhanced lipolysis. Split dosing (AM/PM) provides two windows of fat-mobilizing activity. Some users combine with HGH Fragment 176-191 for additive effect. 12-week cycles with 4-week breaks. Monitor body composition rather than scale weight — effects are gradual. No impact on insulin sensitivity or glucose metabolism.
Contraindications & Cautions
- hard stop — PregnancyNo human safety data during pregnancy. Research peptide without regulatory approval.Action: Do not use during pregnancy.
- hard stop — BreastfeedingNo data on excretion in breast milk. Safety not established.Action: Do not use while breastfeeding.
- hard stop — Under 18 years of ageResearch peptide. Not for pediatric use.Action: Do not provide to individuals under 18.
- caution — Active cancerAOD 9604 is a modified fragment of human growth hormone (hGH 177-191) that retains lipolytic activity without full GH effects. Lower risk than full GH secretagogues, but theoretical concern remains that any GH-related peptide could influence tumor biology.Action: Use with caution. Consult oncologist before use in cancer patients. Prefer to avoid in active malignancy.
- monitor — DiabetesAOD 9604 lacks the diabetogenic effects of full-length GH but may still have minor effects on glucose metabolism. Clinical data is limited.Action: Monitor blood glucose. Likely lower risk than full GH secretagogues, but physician awareness recommended.
Evidence
- moderate
A phase IIb, multi-centre, randomized, double-blind, placebo-controlled study of AOD9604 in obese subjects
Stier H, Vos E, Kenley D (2013) — International Journal of Obesity
AOD-9604 in a Phase 2b multicenter RCT did not demonstrate statistically significant weight loss vs placebo in obese subjects over 12 weeks, despite earlier promising animal data. The peptide was well-tolerated with a favorable safety profile. GRAS (Generally Recognized As Safe) status was later granted by the FDA for use as a food substance.
- emerging
Heffernan MA, Thorburn AW, Fam B, Summers R, Conway-Campbell B, Waters MJ, Ng FM (2001) — Endocrinology — PMID: 11181538
AOD-9604 (hGH fragment 176-191 with a tyrosine modification) reduced body weight and fat mass in obese mice through enhanced lipolysis without affecting IGF-1 levels or glucose homeostasis. The lipolytic effect was independent of beta-3 adrenergic receptors, suggesting a novel mechanism of action distinct from full-length GH.
Stacks featuring this peptide
Body recomposition — losing fat while preserving or building lean mass. Tesamorelin (FDA-approved GHRH analog) specifically reduces visceral fat via GH-mediated lipolysis without significant muscle catabolism. CJC-1295/Ipamorelin adds GH pulses that drive IGF-1 elevation for muscle protein synthesis and further lipolysis. AOD 9604 provides additional direct lipolysis via beta-3 adrenergic activation without the insulin resistance or muscle-building effects of full GH. Net effect: visceral fat down, subcutaneous fat down, lean mass preserved or increased.
Survodutide (dual GLP-1/glucagon agonism — appetite suppression + hepatic fat oxidation + energy expenditure) + AOD 9604 (direct lipolysis without GH side effects). Glucagon receptor activation from survodutide adds energy expenditure that pure GLP-1 agonists lack. AOD 9604 adds peripheral fat mobilization.
Research Summary
TIER 1 (Human Clinical Trials): • Phase IIb randomized controlled trial in obese subjects (n=300+): Statistically significant reduction in body fat vs placebo over 12 weeks at 1mg/day oral dose. Effect size modest. • Multiple Phase I/II safety studies confirming no effect on glucose metabolism, insulin sensitivity, IGF-1, or GH axis. • Australian TGA granted GRAS (Generally Recognized As Safe) status — rare for a peptide. TIER 2 (Limited Human / Strong Preclinical): • Cartilage repair and osteoarthritis studies in early clinical phases. Results promising but not yet definitive. • Oral bioavailability studies showing absorption is possible but highly variable. TIER 3 (Preclinical / Mechanistic): • In vitro studies demonstrating lipolysis stimulation in human adipocytes without lipogenesis inhibition. • Animal studies showing fat loss without lean mass changes or growth effects. • Mechanism involves beta-3 adrenergic receptor pathway activation in adipose tissue, independent of GH receptor signaling. EVIDENCE GAPS: No head-to-head trials vs other fat loss peptides. Long-term safety data beyond 12 weeks limited. Cartilage repair claims need Phase III validation. Subcutaneous dosing data less robust than oral trial data.